Building a Resilient Quantum Patent Portfolio: Winning the Race to File First

​
May 29, 2025

A key question for those working in a fast-paced and complex industry such as quantum technology is when to patent any technological developments. The earlier the filing date of the patent application, the earlier you can start to talk about your invention openly, to potential investors, customers, or other companies seeking to collaborate to commercialise the invention. However, speed is not the sole requirement to win the race: to truly succeed, your patent must be robust too.

A particular challenge of quantum technology is that there can be a significant delay between devising the initial inventive concept and rigorous proof that the invention actually works in practice. At what point should you file your patent application?

There are numerous factors to consider, including how rapidly the technology is evolving and the current priorities of your business, given the funds available. In this article, we will focus on the requirement for patent applications to include a sufficiently detailed explanation of how to carry out the invention, and how this ties into considerations around when to file for patent protection. We will also discuss a sufficiency case study in quantum computing.

Requirement of Sufficiency

The patent process involves a trade-off: the patentee can prevent others from carrying out their invention for a limited amount of time but, in exchange, they must describe how the invention can be performed. Ironing out the details of a working implementation in order to meet this requirement of sufficiency can take a significant amount of time. This means that patentees must tread a delicate path between getting a patent application on file as soon as they can, without filing the application so early that they are unable to fully describe how the invention works.

These issues are particularly relevant for emerging technologies, such as quantum technologies, for which there may be a long road from initial idea to a working prototype, let alone to a commercial product, and where the understanding of the physics underlying an innovative concept is often significantly ahead of the understanding of how to implement the innovative concept in practice. For innovators seeking to change the status quo, there will naturally be a desire to get ahead of the curve by patenting innovative concepts as soon as possible. This could lead to businesses opting to patent before working implementations are fully pinned down, potentially leading to patents that are invalid due to lack of sufficiency.

While a description of a plausible way of putting the invention into effect will usually satisfy patent office examiners, issues relating to sufficiency tend to appear when you least want them to, for example during a due diligence exercise for an investment or for a joint venture opportunity, when the issue of sufficiency may be investigated in more detail. We may therefore see an uptick in sufficiency issues arising for quantum tech patents as the technology matures, and as dealmaking increases within the field.

Certain sufficiency issues can't be fixed after a patent application is filed, and a granted patent that insufficiently describes how to perform the invention may be effectively unenforceable and vulnerable to revocation. It is therefore vital to ensure that the technology to implement an innovative concept is adequately understood and described in the patent application at the time of filing. If there is any uncertainty over how to implement an innovative concept in practice, then there is a risk involved in filing a patent application at that time. Whether it is worthwhile taking that risk involves weighing up the level of uncertainty against the possible benefits of filing early.

Sufficiency Case Study: Topological Qubits

The unveiling by Microsoft in February 2025 of the self-proclaimed "world's first quantum processor powered by topological qubits"[1] raises interesting questions around the validity of patent applications directed towards topological qubits that were filed before this date.

A quick search of published patent applications in the name of Microsoft that mention a "topological qubit" in the title or abstract reveals at least 16 patent families with an earliest effective filing date of before February 2025, with some families filed well before this date. For example, US patent number 8,748,196 has a priority date of way back in November 2010 and includes claims referring to a topological qubit.

Even now, there is debate within the quantum community about whether the structure presented in the Microsoft Nature paper[2] that accompanied the February 2025 announcement is truly a topological qubit or whether it is instead an Andreev state. Particular caution may be merited given Microsoft's previous pronouncements in this space: they were forced to retract a 2018 Nature paper[3] that claimed evidence of topological qubits due to self-confessed "insufficient scientific rigour".

If it is eventually discovered that the structure described in Microsoft's February 2025 Nature paper is not a topological qubit, there is a significant question mark over whether it would have been possible to produce topological qubits claimed in earlier patents based on the description in these earlier patents and the general knowledge in the field at the time of filing. Put another way, if it weren't possible to implement topological qubits as late as February 2025, how would it be possible for patents filed earlier than this to include a description of a working implementation of topological qubits? If this were the case, the validity of patents filed earlier than February 2025 that claim topological qubits would be in serious doubt.

There is also a more philosophical question regarding the meaning of the term "qubit". To distinguish a qubit from e.g. an arbitrary two-level quantum system, there is a sense that a qubit must be (i) preparable into a given state, (ii) controllable into other states, and (iii) measurable. If the techniques for any of (i)-(iii) are non-trivial or not yet well established within the field, then a patent application describing a novel two-level quantum system which could in principle serve as a qubit may not be able to make a claim to a qubit per se without running into sufficiency issues.

For nascent quantum technologies in which companies are seeking foundational patents, striking a balance between future promise and concrete, demonstrated implementation is essential. Otherwise, we could see sufficiency issues making a dramatic impact on the patent landscape, for example if key patents for a particular technology are held to be invalid due to insufficiency.

Conclusion

We expect to see sufficiency play an increasingly prominent part in the assessment of validity of patents in the quantum technology space. Choosing the right moment to patent your innovation in this field will be important to obtain resilient protection that can withstand deep scrutiny and third-party challenges. If you would like to discuss protecting your IP in the quantum technology arena or how to optimise your patent filing strategy, please do get in touch with our Quantiphy team.

[1] Microsoft unveils Majorana 1, the world's first quantum processor powered by topological qubits - Microsoft Azure Quantum Blog

[2]Interferometric single-shot parity measurement in InAs–Al hybrid devices | Nature

[3]Retraction Note: Quantized Majorana conductance | Nature

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​